The impossibility theorem maintains that patients cannot make good choices, but, rather, must be dependent on the well-intentioned decisions of others. Policy makers believe this theorem by definition. But, just to make sure, they have structured the health-insurance system to ensure that patients are never asked or allowed to make price-conscious choices. The arrangement underlies the innumerable rules, subsidies, entitlements, mandates and prohibitions that collectively make health care the least efficient part of the economy. ObamaCare makes it worse.
America’s Health Leaders Strategies & Perspectives
America's Healthcare Leaders
In a recent interview with America’s Healthcare Leaders, a platform to highlight strategic health care leaders, Mark West shares information about his strong background in developing and implementing high-performing procurement and supply chain organizations. West’s experience in supply chain management and in leading organizations in a changing environment uniquely equips him to lead SharedClarity.
SharedClarity Hires Clinical And Health Care Supply Chain Industry Veteran As First National Sales Consultant
SharedClarity has hired a 20-year clinical and health care supply chain industry expert as its first national sales consultant, a critical role for the new venture that is conducting independent studies on the long-term effectiveness of medical devices implanted into patients.
The aim of the CQO movement is to provide first-class quality of care, continuity of care and lower readmissions while reducing costs to an organization, supply chain experts say. It is an approach that requires organizations to examine the intersection of all the factors that touch the supply chain.
As the United States struggles to rein in its growing $2.7 trillion health care bill, the cost of medical devices like joint implants, pacemakers and artificial urinary valves offers a cautionary tale. Like many medical products or procedures, they cost far more in the United States than in many other developed countries.
Outside Review of Clinical Data Finds a Spinal Treatment’s Benefit Overstated
New York Times
Researchers have long argued that a heralded spinal treatment sold by the nation’s largest device maker, Medtronic, was no better than an older one and possibly more risky. Now with the company’s help, they have the proof. The evidence, published on Monday in a medical journal, is the first fruit of a movement aimed at helping doctors and patients make better treatment choices. Its goal is to have companies make clinical data about a drug or a medical device available to a wide range of researchers, not just a few handpicked ones. The development is the latest step in an evolving, decade-long push by patient advocates to make the practice of medicine more transparent.
SharedClarity Names Three Senior Management Leaders – New Venture To Help Health Care Providers Improve Patient Outcomes
“We’re building a new company with an excellent, first-rate team of industry professionals,” said Mark West, president of SharedClarity. “Each of our new vice presidents brings a great deal of experience to serve our members.” SharedClarity announced it has hired three experienced industry professionals for leadership positions with the company.
Three Large Health Systems And Unitedhealthcare Launch New Venture To Study Long-Term Effectiveness Of Medical Devices
Three large U.S. health systems and one of the nation’s leading insurers today launched a new venture to conduct independent studies on the long-term effectiveness of medical devices that are implanted into patients for everything from heart problems to bad knees and hips.
A growing concern within the medical community is the general lack of transparency into the results of medical device/medical clinical trials. About half of all clinical trials ever conducted on techniques and procedures used today have never been revealed – and those that are issued are more likely to be those with favorable results. In fact, trials with flattering or positive results are twice as likely to be published, for both academic research and industry studies. The practice can have a dramatic impact on health care. Physicians, health care organizations and, most of all, patients can be misled into believing that ineffective treatments are worth using or overlook viable competing treatments with this lack of transparency, exposing patients to health risks from inadequate medical devices or prescription drugs.